Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Common Equity (2020 - 2025)

Historic Common Equity for Cellebrite DI (CLBT) over the last 6 years, with Q3 2025 value amounting to $447.7 million.

  • Cellebrite DI's Common Equity rose 5007.07% to $447.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.7 million, marking a year-over-year increase of 5007.07%. This contributed to the annual value of $336.0 million for FY2024, which is 88217.0% up from last year.
  • Cellebrite DI's Common Equity amounted to $447.7 million in Q3 2025, which was up 5007.07% from $408.4 million recorded in Q2 2025.
  • In the past 5 years, Cellebrite DI's Common Equity ranged from a high of $447.7 million in Q3 2025 and a low of -$73.3 million during Q4 2021
  • For the 5-year period, Cellebrite DI's Common Equity averaged around $163.1 million, with its median value being $56.6 million (2022).
  • Its Common Equity has fluctuated over the past 5 years, first crashed by 21495.67% in 2021, then skyrocketed by 146109.49% in 2025.
  • Quarter analysis of 5 years shows Cellebrite DI's Common Equity stood at -$73.3 million in 2021, then surged by 200.71% to $73.9 million in 2022, then plummeted by 53.68% to $34.2 million in 2023, then soared by 882.17% to $336.0 million in 2024, then soared by 33.23% to $447.7 million in 2025.
  • Its Common Equity was $447.7 million in Q3 2025, compared to $408.4 million in Q2 2025 and $363.5 million in Q1 2025.